Find therapies in clinical trials near you

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

Study of Brentuximab Vedotin with Drug Combination for Untreated CD30-expressing Peripheral T-cell Lymphoma Patients

Study of Brentuximab Vedotin with Drug Combination for Untreated CD30-expressing Peripheral T-cell Lymphoma Patients

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients